SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas

被引：3
|
作者：
Hamblett, Kevin J. [1 ]
Cochran, Julia [1 ]
Snead, Katie [1 ]
Jin, Steven [1 ]
Yumul, Roma [1 ]
Simmons, Jessica [1 ]
Stone, Ivan [1 ]
Lyski, Ryan [1 ]
Schrum, Jason P. [1 ]
Lim, Andrea R. [1 ]
Clarke, Astrid [1 ]
机构：
[1] Seagen Inc, Bothell, WA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182400
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML)
    Kennedy, Dana A.
    Alley, Stephen C.
    Zhao, Baiteng
    Feldman, Eric J.
    O'Meara, Megan
    Sutherland, May
    CANCER RESEARCH, 2015, 75
  • [42] SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
    Mazahreh, Rebecca
    Mason, Marsha L.
    Gosink, John J.
    Olson, Devra J.
    Thurman, Robert
    Hale, Christopher
    Westendorf, Lori
    Pires, Thomas A.
    Leiske, Christopher I.
    Carlson, Markus
    Nguyen, Liem T.
    Cochran, Julia H.
    Okeley, Nicole M.
    Yumul, Roma
    Jin, Steven
    Stone, Ivan J.
    Sahetya, Disha
    Nesterova, Albina
    Allred, Sean
    Hensley, Kelly M.
    Hu, Rachael
    Lawrence, Robert
    Lewis, Timothy S.
    Sandall, Sharsti
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (04) : 421 - 434
  • [43] Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies
    Almhanna, Khaldoun
    Prithviraj, Gopi K.
    Veiby, Petter
    Kalebic, Thea
    PHARMACOLOGY & THERAPEUTICS, 2017, 170 : 8 - 13
  • [44] CD6-Targeted Antibody-Drug Conjugate As a Potential Therapeutic Agent for T Cell Lymphomas
    arameswaran, Neetha
    Luo, Liping
    Zhang, Lingjun
    Chen, Joel
    Fox, David A.
    Hsi, Eric D.
    Jagadeesh, Deepa
    Lin, Feng
    BLOOD, 2021, 138
  • [45] A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
    Jin, Yangbing
    Zhang, Zehui
    Zou, Siyi
    Li, Fanlu
    Chen, Hao
    Peng, Chenghong
    Deng, Xiaxing
    Wen, Chenlei
    Shen, Baiyong
    Zhan, Qian
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment
    Ahmad, Rehan
    Panchamoorthy, Govind
    Raina, Deepak
    Lawney, Brian
    Kharbanda, Surender
    Jasuja, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
    Lyon, Robert P.
    Jonas, Mechthild
    Frantz, Christopher
    Trueblood, Esther S.
    Yumul, Roma
    Westendorf, Lori
    Hale, Christopher J.
    Stilwell, Jackie L.
    Yeddula, Narayana
    Snead, Katie M.
    Kumar, Vineet
    Patilea-Vrana, Gabriela I.
    Klussman, Kerry
    Ryan, Maureen C.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12) : 1444 - 1453
  • [48] Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML
    Abrams, Tinya J.
    Niu, Xiaohong
    Embry, Millicent
    Kline, Janine
    Patawaran, Montesa
    Fanton, Christie
    Ison-Dugenny, Marjorie
    Schneider, Tracy
    Miller, Kathy
    Wang, Zhen
    Ghoddusi, Majid
    Cohen, Steven
    Hong, E. Erica
    Lees, Emma
    Schleyer, Siew
    CANCER RESEARCH, 2015, 75
  • [49] Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
    O'Brien, Neil A.
    McDermott, Martina S. J.
    Zhang, Jun
    Gong, Ke Wei
    Lu, Ming
    Hoffstrom, Benjamin
    Luo, Tong
    Ayala, Raul
    Chau, Kevin
    Liang, Min
    Madrid, Athena M.
    Donahue, Timothy R.
    Glaspy, John A.
    Presta, Leonard
    Slamon, Dennis J.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12) : 1365 - 1375
  • [50] ROBUST ANTITUMOR ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE SGN-35 WHEN ADMINISTERED EVERY 3 WEEKS TO PATIENTS WITH RELAPSED OR REFRACTORY CD30 POSITIVE HEMATOLOGIC MALIGNANCIES IN A PHASE 1 STUDY
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Kennedy, D. A.
    Sievers, E. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 205 - 205
12345